company background image
POAI

Predictive Oncology NasdaqCM:POAI Stock Report

Last Price

US$0.38

Market Cap

US$30.0m

7D

-6.8%

1Y

-71.0%

Updated

26 Sep, 2022

Data

Company Financials
POAI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

POAI Stock Overview

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States.

Predictive Oncology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Predictive Oncology
Historical stock prices
Current Share PriceUS$0.38
52 Week HighUS$1.47
52 Week LowUS$0.25
Beta1.32
1 Month Change-7.79%
3 Month Change-10.30%
1 Year Change-71.05%
3 Year Change-92.43%
5 Year Change-97.44%
Change since IPO-99.99%

Recent News & Updates

Sep 16

Predictive Oncology announces retirement of CEO Mel Engle

Predictive Oncology (NASDAQ:POAI) has announced that J. Melville Engle will retire as CEO and as Chairman and a member of the company’s Board of Directors. To ensure a smooth transition of his responsibilities, Mr. Engle will continue to serve in his role through October 31, 2022. Pursuant to policies regarding leadership succession, the governance committee of POAI’s Board of Directors is working with a succession plan to replace Mr. Engle as CEO. POAI +5.56% after hours to $0.38.

Shareholder Returns

POAIUS Medical EquipmentUS Market
7D-6.8%-7.2%-6.9%
1Y-71.0%-32.3%-23.7%

Return vs Industry: POAI underperformed the US Medical Equipment industry which returned -32.8% over the past year.

Return vs Market: POAI underperformed the US Market which returned -23% over the past year.

Price Volatility

Is POAI's price volatile compared to industry and market?
POAI volatility
POAI Average Weekly Movement7.9%
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: POAI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: POAI's weekly volatility has decreased from 13% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200231Mel Englehttps://www.predictive-oncology.com

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation.

Predictive Oncology Fundamentals Summary

How do Predictive Oncology's earnings and revenue compare to its market cap?
POAI fundamental statistics
Market CapUS$29.96m
Earnings (TTM)-US$26.96m
Revenue (TTM)US$1.48m

20.3x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
POAI income statement (TTM)
RevenueUS$1.48m
Cost of RevenueUS$489.91k
Gross ProfitUS$986.41k
Other ExpensesUS$27.94m
Earnings-US$26.96m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin66.82%
Net Profit Margin-1,825.94%
Debt/Equity Ratio0%

How did POAI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is POAI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for POAI?

Other financial metrics that can be useful for relative valuation.

POAI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA-0.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does POAI's PS Ratio compare to its peers?

POAI PS Ratio vs Peers
The above table shows the PS ratio for POAI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average0.4x
SIEN Sientra
0.4x16.2%US$32.8m
QTNT Quotient
0.5x37.7%US$20.8m
RMTI Rockwell Medical
0.2x18.0%US$13.7m
SRGA Surgalign Holdings
0.3x14.9%US$23.3m
POAI Predictive Oncology
20.3xn/aUS$30.0m

Price-To-Sales vs Peers: POAI is expensive based on its Price-To-Sales Ratio (20.3x) compared to the peer average (0.4x).


Price to Earnings Ratio vs Industry

How does POAI's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: POAI is expensive based on its Price-To-Sales Ratio (20.3x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is POAI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

POAI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate POAI's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of POAI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate POAI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate POAI's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Predictive Oncology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.9%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Predictive Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Predictive Oncology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Predictive Oncology performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-30.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: POAI is currently unprofitable.

Growing Profit Margin: POAI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: POAI is unprofitable, and losses have increased over the past 5 years at a rate of 30% per year.

Accelerating Growth: Unable to compare POAI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: POAI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).


Return on Equity

High ROE: POAI has a negative Return on Equity (-80.38%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Predictive Oncology's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: POAI's short term assets ($29.8M) exceed its short term liabilities ($2.8M).

Long Term Liabilities: POAI's short term assets ($29.8M) exceed its long term liabilities ($135.2K).


Debt to Equity History and Analysis

Debt Level: POAI is debt free.

Reducing Debt: POAI had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: POAI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: POAI has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 19.3% each year.


Discover healthy companies

Dividend

What is Predictive Oncology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Predictive Oncology Dividend Yield vs Market
How does Predictive Oncology dividend yield compare to the market?
SegmentDividend Yield
Company (Predictive Oncology)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Medical Equipment)1.9%
Analyst forecast in 3 Years (Predictive Oncology)n/a

Notable Dividend: Unable to evaluate POAI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate POAI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if POAI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if POAI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as POAI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Mel Engle (72 yo)

1.5yrs

Tenure

US$553,016

Compensation

Mr. J. Melville Engle, also known as Mel, has been President and Chief Executive Officer of Engle Strategic Solutions since 2012. Mr. Engle has many years of management experience in the healthcare industr...


CEO Compensation Analysis

Mel Engle's Compensation vs Predictive Oncology Earnings
How has Mel Engle's remuneration changed compared to Predictive Oncology's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$27m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$553kUS$391k

-US$20m

Sep 30 2021n/an/a

-US$23m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$71kn/a

-US$26m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$117kn/a

-US$20m

Sep 30 2019n/an/a

-US$9m

Jun 30 2019n/an/a

-US$8m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018US$40kn/a

-US$10m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$6m

Dec 31 2017US$164kn/a

-US$6m

Compensation vs Market: Mel's total compensation ($USD553.02K) is about average for companies of similar size in the US market ($USD780.01K).

Compensation vs Earnings: Mel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: POAI's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: POAI's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:POAI Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 May 22BuyUS$955Daniel HandleyIndividual2,550US$0.37
25 May 22BuyUS$980Daniel HandleyIndividual2,800US$0.35
24 May 22BuyUS$59,334J. EngleIndividual159,500US$0.37
20 May 22BuyUS$4,889Robert MyersIndividual16,125US$0.30
20 May 22BuyUS$62,320Charles NuzumIndividual200,000US$0.31

Ownership Breakdown

What is the ownership structure of POAI?
Owner TypeNumber of SharesOwnership Percentage
Private Companies530.0%
Individual Insiders3,103,9814.0%
Institutions5,419,9426.9%
General Public69,860,36389.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.8%.


Top Shareholders

Top 25 shareholders own 10.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
2.71%
The Vanguard Group, Inc.
2,126,663$812.8k0%no data
2.67%
Carl Schwartz
2,091,695$799.4k0%no data
1.13%
Sabby Management, LLC
882,063$337.1k0%0.51%
0.83%
Geode Capital Management, LLC
647,404$247.4k0.99%no data
0.52%
Renaissance Technologies LLC
405,100$154.8k2582.78%no data
0.42%
Charles Nuzum
330,868$126.5k15.62%no data
0.31%
State Street Global Advisors, Inc.
244,732$93.5k0%no data
0.29%
T. Rowe Price Group, Inc.
227,900$87.1k0%no data
0.26%
Carnegie Mellon University Endowment Arm
207,144$79.2k0%0.04%
0.26%
J. Engle
203,393$77.7k363.38%no data
0.2%
RB Capital Management, LLC
159,500$61.0k0%0.03%
0.14%
Nancy Chung-Welch
108,844$41.6k69.7%no data
0.14%
Sax Wealth Advisors, LLC
107,437$41.1k0%0.01%
0.12%
Gregory St. Clair
97,400$37.2k84.83%no data
0.11%
Northern Trust Global Investments
83,096$31.8k-7.93%no data
0.1%
Daniel Handley
81,366$31.1k63.83%no data
0.092%
Christina Jenkins
71,987$27.5k78.69%no data
0.09%
Virtu Financial LLC, Asset Management Arm
70,356$26.9k4.78%no data
0.079%
Raymond Vennare
62,063$23.7k104.4%no data
0.051%
Tower Research Capital LLC
39,927$15.3k13164.78%no data
0.05%
Robert Myers
39,336$15.0k69.47%no data
0.04%
BNY Mellon Asset Management
31,376$12.0k-0.67%no data
0.035%
Private Advisor Group, LLC
27,805$10.6k0%no data
0.032%
Csenge Advisory Group, Llc, Asset Management Arm
25,000$9.6k11.11%no data
0.032%
Scotiabank Global Banking and Markets, Asset Management Division
25,000$9.6k1.77%no data

Company Information

Predictive Oncology Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Predictive Oncology Inc.
  • Ticker: POAI
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: US$29.958m
  • Shares outstanding: 78.38m
  • Website: https://www.predictive-oncology.com

Number of Employees


Location

  • Predictive Oncology Inc.
  • 2915 Commers Drive
  • Suite 900
  • Eagan
  • Minnesota
  • 55121
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
POAINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2009
S1K2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2009

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/26 00:00
End of Day Share Price2022/09/26 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.